Abstract
Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.
Keywords: COVID-19; coronavirus; immunosuppression; kidney transplantation; pandemic; tocilizumab.
【저자키워드】 COVID-19, coronavirus, pandemic, Tocilizumab, Immunosuppression, Kidney transplantation, 【초록키워드】 Treatment, therapy, Lopinavir/ritonavir, Hydroxychloroquine, severe COVID-19, Tocilizumab, SARS-COV-2 infection, antiviral drugs, Lopinavir, Ritonavir, Immunosuppression, antiviral drug, kidney, management, Patient, immunosuppressed patients, Interaction, Atypical, Immunosuppressed, steroid, clinical complication, investigated, treated, immunosuppressed patient, 【제목키워드】 Severe COVID-19 pneumonia, therapy, Tocilizumab,